Cargando…

Update on the use of rituximab for intractable rheumatoid arthritis

It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an inadequate response to anti-TNF therapies. Since approval rituximab has bec...

Descripción completa

Detalles Bibliográficos
Autor principal: Looney, R John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074725/
https://www.ncbi.nlm.nih.gov/pubmed/27789983